Beck Filippo Th.
Kommentar zu Art. 17a HMG
08.12.21
In: Eichenberger/Jaisli/Richli (Hrsg.), Basler Kommentar zum Heilmittelgesetz, 2. Aufl., Basel, 2022
Conti Carlo / Herzfeld Adam / Künzler Oliver
The Pharma Legal Handbook
06.09.21
Regulatory, Pricing and Reimbursement Overview · Preclinical and Clinical Trial Requirements · Marketing, Manufacturing, Packaging and Labeling Advertising · Traditional Medicines and OTC Products · Product Liability · Patents and Trademarks · Regulatory Reforms · Cannabinoid Drugs, Medicinal Cannabis and Opioid Drugs · Orphan Drugs and Rare Diseases · Localization · Biosimilars and Biologics | Pharma Boardroom, 2021
Braun Martina / Conti Carlo / Künzler Oliver
GLI - Pricing & Reimbursement 2021
23.08.21
GLI – Pricing & Reimbursement 2021, Fourth Edition, p. 195 - 204
Braun Martina
Beurteilung der Wirtschaftlichkeit von Arzneimitteln im Rahmen der dreijährlichen Überprüfung
20.10.20
Urteil Bundesverwaltungsgerichts BVGer C-6093/2018 vom 17. März 2020, LSR 2020, S. 163
Braun Martina / Conti Carlo / Künzler Oliver
GLI - Pricing & Reimbursement 2020
24.08.20
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are, in principle, granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare. In general, therapeutic products are only reimbursed if they are listed on the so-called specialty list. In order to be listed thereon, a medicinal product must be admitted by the competent Swiss authority, and must satisfy the criteria of effectiveness, functionality and economic efficiency, based on which the maximum price for the therapeutic product in question is determined.
Conti Carlo / Herzfeld Adam / Künzler Oliver
The Pharma Legal Handbook Switzerland
30.03.20
Regulatory, Pricing and Reimbursement Overview · Preclinical and Clinical Trial Requirements · Marketing, Manufacturing, Packaging and Labeling Advertising · Traditional Medicines and OTC Products · Product Liability · Patents and Trademarks · Regulatory Reforms | Pharma Board Room, London 2020
Braun Martina / Conti Carlo / Künzler Oliver
GLI - Pricing & Reimbursement 2019
02.10.19
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are, in principle, granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare. In general, therapeutic products are only reimbursed if they are listed on the so-called specialty list. In order to be listed thereon, a medicinal product must be admitted by the competent Swiss authority, and has to satisfy the criteria of effectiveness, functionality and economic efficiency, based on which the maximum price for the therapeutic product in question is determined.
Aktuelle Entwicklungen im Bereich Life Sciences
02.10.19
Tagungsbericht zum Seminar des Europa Instituts an der Universität Zürich vom 2. Oktober 2018 in Zürich, in Life Science Recht (LSR) 1/2019, S. 53-59
Berne André S.
Big Data in the Pharmaceutical Sector – Between Protection and Transparency
01.05.19
European Pharmaceutical Law Review EPLR, 2019, S. 37 ff.
Braun Martina / Conti Carlo / Künzler Oliver
GLI – Pricing & Reimbursement 2018
31.05.18
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are in principle granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare.